Hansen Gwenn sold $109K of NRIX
Hansen Gwenn (Chief Scientific Officer) sold 4,356 shares of Nurix Therapeutics, Inc. (NRIX) at $25.00 ($0.11M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed open-market sale at a fixed price under a 10b5-1 plan is typically treated as routine compliance disclosure rather than a fundamental catalyst.
Market read
Traders may note insider selling for sentiment, but the 10b5-1 structure and lack of fundamental updates make it low-impact.
What to watch
The article provides only the sale details, not total planned volume, timing of future sales, or whether other insiders are selling/buying concurrently.
Background
The article is a SEC Form 4 insider transaction for Nurix Therapeutics, reported by its Chief Scientific Officer.
Ticker impact
Nurix Therapeutics CSO Hansen Gwenn sold 4,356 shares in an open-market transaction at $25.00 on 2026-08-05 under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely muted.
The filing is an insider transaction disclosure, not guidance, trial data, or a corporate action. The presence of a 10b5-1 plan reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through; this is company-specific insider trading disclosure.
None.
None.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s view of valuation or liquidity needs, which some traders may interpret as mild bearish sentiment.
Key entities
- issuerNurix Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderHansen Gwenn
Chief Scientific Officer who sold shares under a pre-arranged 10b5-1 plan.
